Ifosfamide Eg (Ifosfamide)

Ifosfamide is a pro‑drug that is activated in the liver by cytochrome P450 enzymes. The active metabolite alkylates DNA, forming cross‑links that block DNA replication and transcription, which leads to programmed cell death of rapidly dividing tumor cells.

The dosing regimen for ifosfamide is individualized by the prescribing oncologist based on the specific cancer type, stage, patient weight, renal function and treatment protocol. Only a qualified healthcare professional should determine the appropriate dose and schedule.

Safety data for ifosfamide in pregnancy and lactation are limited, and the drug may pose risks to the fetus or infant. It is generally avoided in pregnant or nursing women unless the potential benefit justifies the potential risk, and this decision must be made by the treating physician.

To request Ifosfamide Eg, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Ifosfamide shares a similar mechanism of DNA alkylation with other agents such as cyclophosphamide, but it has a distinct metabolic activation pathway and a broader spectrum of activity against certain sarcomas and CNS tumours. Its toxicity profile, including a higher risk of hemorrhagic cystitis, often requires co‑administration of protective agents like mesna.

Ifosfamide Eg should be stored at 2‑8 °C, protected from light, and kept in its original packaging to maintain stability. Do not freeze the product, and avoid shaking the vial. Follow local pharmacy guidelines for handling cytotoxic agents.

Ifosfamide Eg is supplied for intravenous infusion. It is reconstituted according to the manufacturer’s instructions and administered by a qualified healthcare professional, typically over a period of 1–3 hours, with appropriate hydration and protective measures such as mesna to reduce bladder toxicity.

The most serious adverse effects include nephrotoxicity, encephalopathy, severe myelosuppression (leading to infection or bleeding), and hemorrhagic cystitis. Patients should be closely monitored for renal function, neurological status and blood counts throughout treatment.

Patients with known hypersensitivity to ifosfamide or its excipients, those with severe renal impairment, uncontrolled infections, or who are pregnant without a clear therapeutic justification should not receive ifosfamide. The prescribing clinician must evaluate each individual’s medical history before initiating therapy.